BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Daiichi Sankyo

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,275,063

« Back to Dashboard

Summary for Patent: 4,275,063

Title: Pharmaceutical compositions
Abstract:A pharmaceutical composition useful for aiding regression and palliation of sarcoma, lymphosarcoma and leukaemia in mammals comprises a therapeutically effective amount of a compound of formula ##STR1## wherein R.sub.1 and R.sub.2 are each separately selected from hydrogen and methyl or together represent an ethylene bridging group, with the proviso that when both of the groups R.sub.1 and R.sub.2 are methyl they are disposed in the meso configuration, or a non-toxic salt thereof with a physiologically acceptable inorganic or organic acid, in combination with a physiologically acceptable diluent or carrier.
Inventor(s): Creighton; Andrew M. (London, GB2)
Assignee: National Research Development Corporation (GB2)
Application Number:05/768,287
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use; Delivery;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,275,063

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom30617/67Jul 03, 1967

International Patent Family for Patent: 4,275,063

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia3683771► Subscribe
Australia470566► Subscribe
Belgium729217► Subscribe
Belgium776958► Subscribe
Canada1002049► Subscribe
Canada922720► Subscribe
Canada941378► Subscribe
Canada943133► Subscribe
Switzerland563996► Subscribe
Switzerland563997► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus